Johnson & Johnson CEO Alex Gorsky: 5 things to know on 2017

Written by Laura Dyrda | January 25, 2017 | Print  |

Johnson & Johnson's CEO Alex Gorsky will make responsible drug pricing a priority in the coming year after meeting with President Donald Trump, according to a Yahoo Finance report.

Here are five key notes:

 

1. After the meeting, Mr. Gorsky said he would like to see changes to the U.S. tax code and healthcare policy.

 

2. Johnson & Johnson had a turbulent start to the year, with 2016 fourth quarter sales falling short of expectations.

 

3. Johnson & Johnson was the first major healthcare company to report sales after Mr. Trump criticized the high prices of medications. The company reported it would limit annual product price increases to single digits in percentage terms.

 

4. The company is planning to release a pharmaceutical transparency report and expand disclosures on U.S. pricing, research and development expenses.

 

5. Mr. Gorsky said the company will also disclose compassionate care programs.

 

More articles on orthopedic devices:
Zimmer Biomet, Implanet, Spinal Elements & more: 8 device company key notes
SpineFrontier improves MISquito Percutaneous Pedicle Screw System: 7 key points
Orthofix reports final resolution to SEC investigations: 6 insights

© Copyright ASC COMMUNICATIONS 2019. Interested in LINKING to or REPRINTING this content? View our policies here.

Top 40 Articles from the Past 6 Months